Rates and Trends of Pediatric Acute Lymphoblastic Leukemia — United States, 2001–2014
Weekly / September 15, 2017 / 66(36);950–954
David A. Siegel, MD1,2; S. Jane Henley, MSPH2; Jun Li, MD, PhD2; Lori A. Pollack, MD2; Elizabeth A. Van Dyne, MD1,2; Arica White, PhD2 (View author affiliations)View suggested citation
What is already known about this topic?
Acute lymphoblastic leukemia (ALL) is the most common cancer in children and adolescents in the United States. Past studies using ≤28% population coverage have described increasing incidence of pediatric ALL, especially in Hispanic populations.
What is added by this report?
Analysis of data covering 98% of the U.S. population indicated that the incidence of pediatric ALL increased during 2001–2008 overall and for Hispanics, but then was stable during 2008–2014. The cause for the higher rates of ALL in Hispanic populations and the increase during 2001–2008 is unknown. Incidence of pediatric leukemia during 2001–2014 was highest in the West U.S. Census Region, possibly reflecting the high proportion of Hispanics in many of the region’s constituent states.
What are the implications for public health practice?
Increasing incidence of pediatric ALL in certain demographic groups might necessitate changes to cancer control planning, affecting treatment and survivorship care. Continued cancer surveillance will be important in guiding future research, including etiologic studies.
Acute lymphoblastic leukemia (ALL) is the most prevalent cancer among children and adolescents in the United States, representing 20% of all cancers diagnosed in persons aged <20 years, or >3,000 new cases each year (1). Past studies reported increasing trends of ALL overall and among Hispanics, but these represented ≤28% of the U.S. population and did not provide state-based estimates (1–3). To describe U.S. ALL incidence rates and trends among persons aged <20 years during 2001–2014, CDC analyzed rigorous data (based on established publication criteria) from the United States Cancer Statistics data set, which includes incidence data on approximately 15,000 new cases per year of all types of invasive cancer among children and adolescents aged <20 years (4). The data set represented 98% of the U.S. population during the study period. Overall incidence of pediatric ALL during 2001–2014 was 34.0 cases per 1 million persons and among all racial/ethnic groups was highest among Hispanics (42.9 per 1 million). Both overall and among Hispanics, pediatric ALL incidence increased during 2001–2008 and remained stable during 2008–2014. ALL incidence was higher in the West than in any other U.S. Census region. State-specific data indicated that the highest rates of pediatric ALL incidence were in California, New Mexico, and Vermont. These demographic and geographic ALL incidence data might better inform public health interventions targeting the following areas: exposures to recognized risk factors for leukemia; ALL treatment, including clinical trial enrollment; survivorship care planning; and studies designed to understand the factors affecting changes in pediatric cancer incidence.
The United States Cancer Statistics data set includes cancer incidence data from CDC’s National Program of Cancer Registries and the National Cancer Institute’s Surveillance, Epidemiology, and End Results program (4). Data on new cases of cancer diagnosed during 2001–2014 were obtained from population-based cancer registries affiliated with the National Program of Cancer Registries or Surveillance, Epidemiology, and End Results programs. Incidence data for all registries except the District of Colombia, Mississippi, and Nevada met United States Cancer Statistics publication criteria during 2001–2014, and represented 98% of the U.S population.* This report includes cases diagnosed among children and adolescents aged <20 years and includes International Classification of Diseases for Oncology, Third Edition† codes 9728–9729, 9811–9818, and 9835–9837 as grouped by the International Classification of Childhood Cancer.§ Cases were included if ALL was the first or only cancer diagnosed and was confirmed microscopically or by positive laboratory test or marker study. Recurrent cases of ALL were not included in this report.
Age-adjusted rates were calculated using statistical software. All rates were expressed per 1 million persons and were age-adjusted to the 2000 U.S. standard population.¶ Age-adjusted incidence trends were quantified using annual percent change (APC) calculated using joinpoint regression. Statistically significant APCs were different from zero (p<0.05). A maximum of two joinpoints were used to determine a change of direction in trends during the study period. Rates and trends were estimated by sex, age group, race/ethnicity, state, U.S. Census region,** county-level economic status, and rural/urban status.
During 2001–2014, a total of 38,136 new pediatric ALL cases were diagnosed in the United States (Table). Overall incidence of ALL was 34.0 cases per 1 million. Rates were highest in children aged 1–4 years (75.2 per 1 million) and were higher in males (38.0) than in females (29.7). Among all racial/ethnic groups, the highest incidence rate (42.9 per 1 million) was among Hispanics, followed by non-Hispanic whites (34.2 per 1 million). The lowest incidence (18.7) occurred among non-Hispanic blacks. Pediatric ALL incidence rates in the 25% of U.S. counties with the highest economic status were higher than rates in the 25% of counties with the lowest economic status and were higher in metropolitan areas with ≥1 million persons than in nonmetropolitan areas. Rates were highest in the West (38.5) followed by the Northeast (34.8), Midwest (32.4), and South (31.6) Census regions, and, among states, were highest in Vermont (41.9), California (40.8), and New Mexico (39.1) (Figure 1) (Supplementary Table 1, https://stacks.cdc.gov/view/cdc/47662). State-specific ALL incidence by race/ethnicity ranged from 10.1–27.9 per 1 million among non-Hispanic blacks to 25.1–45.0 among non-Hispanic whites and 27.3–48.5 among Hispanics (Supplementary Table 2, https://stacks.cdc.gov/view/cdc/47663).
Overall pediatric ALL incidence increased 1.9% per year during 2001–2008, and then remained stable during 2008–2014 (Figure 2). Incidence increased among males during 2001–2008 and among children aged 5–9 years and 10–14 years during 2001–2010 and 2001–2014, respectively, as well as in metropolitan areas with populations ≥1 million during 2001–2008 (Table). Among Hispanics, rates increased during 2001–2008 (APC 2.5, 95% confidence interval = 0.3–4.7) and were stable (nonsignificant decrease) during 2008–2014; pediatric ALL incidence rates were stable in all other racial/ethnic groups. State-specific analysis indicated that pediatric ALL incidence increased during all or part of 2001–2014 in four states: Alabama, Maryland, Massachusetts, and New York (Supplementary Table 1, https://stacks.cdc.gov/view/cdc/47662).
Consistent with other published data, this analysis found that rates of ALL were highest in males, children aged 1–4 years, and Hispanics (1). Rates varied by state and region and were highest in the West U.S. Census Region. This report, using more recent data with broader population coverage than past studies (1–3), confirms an increase in pediatric ALL overall and among Hispanics (2001–2008) and also documents a subsequent period of stable trends overall and among Hispanics (2008–2014).
High rates of pediatric ALL in the Hispanic population might explain high ALL rates in the West U.S. Census Region and in other specific states, given the high proportion of Hispanics in many of these areas.†† Past studies documenting increasing incidence of pediatric ALL in Hispanics focused on earlier periods using the Surveillance, Epidemiology, and End Results database or the California Cancer Registry (2,3). Recent stable trends in ALL rates in Hispanic populations (2008–2014) might indicate a change after 2 decades of documented increasing trends. The cause for the higher rates of ALL in Hispanic populations and the increase during 2001–2008 is unknown; however, past studies have evaluated such factors as genetic susceptibility, disproportionate environmental exposure to household chemicals, or racial and ethnic disparities in parents’ exposures to chemicals at work (2,3). Other studies have hypothesized that the increasing trends in obesity among Hispanics might explain the increasing trends of ALL incidence among this population (2).
This report documents higher rates of ALL in persons aged <20 years living in counties in metropolitan areas with ≥1 million population and in counties in the top 25th income percentile. Past studies of pediatric leukemia have investigated possible associations with higher economic status or increased exposure to air pollution that is often found in large metropolitan areas (5,6). Etiologic studies examining potential causes of pediatric leukemia have documented associations between leukemia and exposures to solvents, traffic, pesticides, tobacco smoke, or radiation, or to specific nutritional exposures (7).
The findings in this report are subject to at least five limitations. First, the District of Columbia, Mississippi, and Nevada were excluded because of incomplete trend data, which limits the representativeness of the results. Second, although the United States Cancer Statistics data publication standards yield high quality data, misclassifications of race and ethnicity exist and might underestimate rates in American Indians, Alaska Natives, and Hispanics (8); ongoing procedures are used to ensure that this information is as accurate as possible. Third, the U.S. Census population estimates used in rate denominators might undercount some groups, including children and Hispanics, which could artificially raise incidence rates (3). Fourth, improvement in case ascertainment through advancements in electronic pathology reporting might affect trends: rates might appear to increase because current cancer registration methods are more accurately recording cases that were previously under-recorded. Finally, the possibility of a statistical error exists when analyzing subgroups with small numbers. Although APCs that are close to the significance cutoff might be truly significant, future studies will be needed to validate and monitor trends.
These recent state-based demographic cancer data can help local and national cancer control programs assess needs, allocate resources, and guide policy and public health strategies that can reduce cancer risk and improve the care of children and adolescents with ALL. Because cancer clinical trial participation has become an increasingly important part of quality clinical care (9), many state health departments have created cancer control plans that aim to address the economic and sociocultural barriers that limit certain groups enrolling in these trials.§§ Knowledge about rates and trends of pediatric ALL might help tailor the goals of these programs to address local and disease-specific needs. In addition, as incidence and survival of pediatric ALL increase (1), public health professionals can use recent ALL incidence data to improve local cancer survivorship programs that address chronic disease management, screen for late effects, and provide resources to help patients maintain a high quality of life (10). Public health planners can prioritize issues pertinent to pediatric cancer survivors such as transitioning to adult care and accessing the educational resources that might be available to these patients. Finally, health care professionals and researchers can use surveillance data to inform research questions. Continued surveillance data will be needed to further track incidence changes and public health needs relative to specific demographic groups and geographic areas.
Jessica King, Simple Singh, Mary White, Reda Wilson; state and regional cancer registry and health department personnel.
Conflict of Interest
No conflicts of interest were reported.
Corresponding author: David A. Siegel, email@example.com, 770-488-4426.
* Cancer registries’ incidence data met the following five United States Cancer Statistics criteria: 1) ≤5% of cases ascertained solely on the basis of death certificate; 2) ≤3% of cases missing information on sex; 3) ≤3% of cases missing information on age; 4) ≤5% of cases missing information on race; and 5) ≥97% of registry’s records passed a set of single-field and inter-field computerized edits that test the validity and logic of data components. https://nccd.cdc.gov/uscs/.
§ https://seer.cancer.gov/iccc/iccc-who2008.htmlExternal. “ALL” in this study includes precursor cell leukemia and lymphoma International Classification of Diseases for Oncology, Third Edition codes, excluding code 9727 because of its use to code for blastic plasmacytoid dendritic cell neoplasm. Additional information is available at http://onlinelibrary.wiley.com/doi/10.1002/cncr.20910/fullExternal and http://www.bloodjournal.org/content/114/5/937?sso-checked=trueExternal.
¶ Population estimates incorporate bridged single-race estimates derived from the original multiple race categories in the 2010 U.S. Census. https://seer.cancer.gov/popdataExternal.
- Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 2014;64:83–103. CrossRefExternal PubMedExternal
- Barrington-Trimis JL, Cockburn M, Metayer C, Gauderman WJ, Wiemels J, McKean-Cowdin R. Trends in childhood leukemia incidence over two decades from 1992 to 2013. Int J Cancer 2017;140:1000–8. CrossRefExternal PubMedExternal
- Giddings BM, Whitehead TP, Metayer C, Miller MD. Childhood leukemia incidence in California: high and rising in the Hispanic population. Cancer 2016;122:2867–75. CrossRefExternal PubMedExternal
- US Cancer Statistics Working Group; CDC; National Cancer Institute. United States cancer statistics: 1999–2014 incidence and mortality web-based report. Atlanta, GA: US Department of Health and Human Services, CDC; 2017. https://www.cdc.gov/uscs
- Adam M, Rebholz CE, Egger M, Zwahlen M, Kuehni CE. Childhood leukaemia and socioeconomic status: what is the evidence? Radiat Prot Dosimetry 2008;132:246–54. CrossRefExternal PubMedExternal
- Filippini T, Heck JE, Malagoli C, Del Giovane C, Vinceti M. A review and meta-analysis of outdoor air pollution and risk of childhood leukemia. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2015;33:36–66. CrossRefExternal PubMedExternal
- Metayer C, Dahl G, Wiemels J, Miller M. Childhood leukemia: a preventable disease. Pediatrics 2016;138(Suppl 1):S45–55. CrossRefExternal PubMedExternal
- Gomez SL, Glaser SL. Misclassification of race/ethnicity in a population-based cancer registry (United States). Cancer Causes Control 2006;17:771–81. CrossRefExternal PubMedExternal
- Institute of Medicine Committee on Cancer Clinical Trials; NCI Cooperative Group Program. In: Nass SJ, Moses HL, Mendelsohn J, eds. A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program. Washington, DC: The National Academies Press; 2010.
- Ryerson AB, Eheman C, Styles T, Rycroft R, Snyder C. Connecting the dots: linking the National Program of Cancer Registries and the needs of survivors and clinicians. Am J Prev Med 2015;49(Suppl 5):S528–35. CrossRefExternal PubMedExternal
TABLE. Age-adjusted incidence* of acute lymphoblastic leukemia† in persons aged <20 years and annual percentage change (APC) in rates, by selected characteristics — United States,§ 2001–2014
|Characteristic||No.||Incidence (95% CI)||APC¶|
|Years||APC1 (95% CI)||Years||APC2 (95% CI)||Years||APC3 (95% CI)|
|Overall||38,136||34.0 (33.6–34.3)||2001–2008||1.9 (0.5–3.3)**||2008–2014||-1.1 (–2.8–0.6)||—††||—|
|Male||21,871||38.0 (37.5–38.5)||2001–2008||2.1 (0.5–3.7)**||2008–2014||-1.5 (-3.3–0.4)||—||—|
|Female||16,265||29.7 (29.2–30.1)||2001–2003||-4.0 (-14.7–8.1)||2003–2008||3.2 (-0.5–7.0)||2008–2014||-1.0 (-2.9–0.9)|
|Age group (yrs)|
|<1||1,009||18.4 (17.3–19.6)||2001–2014||-1.5 (-3.3–0.3)||—††||—||—||—|
|1–4||16,388||75.2 (74.0–76.4)||2001–2009||1.3 (-0.1–2.8)||2009–2014||-2.4 (-5.2–0.5)||—||—|
|5–9||9,535||34.8 (34.1–35.5)||2001–2010||2.2 (1.3–3.2)**||2010–2014||-1.7 (-4.6–1.3)||—||—|
|10–14||6,201||21.6 (21.1–22.1)||2001–2014||1.3 (0.5–2.1)**||—||—||—||—|
|15–19||5,003||17.0 (16.5–17.5)||2001–2014||0.4 (-0.5–1.3)||—||—||—||—|
|White||21,843||34.2 (33.8–34.7)||2001–2014||0.3 (-0.3–0.9)||—||—||—||—|
|Black||3,129||18.7 (18.0–19.3)||2001–2014||1.2 (-0.1–2.7)||—||—||—||—|
|Hispanic||10,595||42.9 (42.1–43.7)||2001–2008||2.5 (0.3–4.7)**||2008–2014||-1.8 (-4.2–0.6)||—||—|
|American Indian/Alaska Native||350||30.2 (27.1–33.6)||2001–2014||-1.9 (-4.2–0.5)||—||—||—||—|
|Asian/Pacific Islander||1,765||31.6 (30.1–33.1)||2001–2014||0.3 (-0.9–1.6)||—||—||—||—|
|U.S. Census region¶¶|
|Northeast||—***||34.8 (34.0–35.6)||2001–2007||3.0 (0.2–6.0)**||2007–2014||-1.6 (-3.7–0.7)||—||—|
|Midwest||—||32.4 (31.7–33.2)||2001–2011||1.6 (0.6–2.6)**||2011–2014||-5.4 (-11.4–1.0)||—||—|
|South||—||31.6 (31.0–32.1)||2001–2003||-4.6 (-15.3–7.6)||2003–2008||3.9 (0.2–7.7)**||2008–2014||-1.3 (-3.2–0.5)|
|West||—||38.5 (37.8–39.3)||2001–2014||0.4 (-0.3–1.1)||—||—||—||—|
|County-level economic status by percentile (%)|
|Bottom 25||4,182||32.2 (31.2–33.2)||2001–2014||1.4 (0.6–2.2)**||—||—||—||—|
|25–75||22,141||33.9 (33.4–34.3)||2001–2010||1.1 (0.2–2.1)**||2010–2014||-2.4 (-5.5–0.9)||—||—|
|Top 25||10,646||34.9 (34.2–35.6)||2001–2008||2.9 (0.7–5.1)**||2008–2014||-1.5 (-4.0–1.1)||—||—|
|Metropolitan area ≥1 million population||21,690||35.7 (35.3–36.2)||2001–2008||2.7 (1.2–4.2)**||2008–2014||-1.6 (-3.4–0.2)||—||—|
|Metropolitan area 250,000 to <1 million population||8,134||34.4 (33.7–35.2)||2001–2011||0.8 (-0.4–2.1)||2011–2014||-4.4 (-11.8–3.7)||—||—|
|Metropolitan area <250,000 population||3,302||33.8 (32.7–35.0)||2001–2014||0.6 (-0.3–1.5)||—||—||—||—|
|Nonmetropolitan counties||4,962||32.9 (32.0–33.9)||2001–2014||0.9 (0.0–1.8)||—||—||—||—|
FIGURE 1. Annual age-adjusted rates* of acute lymphoblastic leukemia among persons aged <20 years, by state — National Program of Cancer Registries, and Surveillance, Epidemiology, and End Results program, United States, 2001–2014
* Rates are per 1 million persons and age-adjusted to the 2000 U.S. standard population.
The figure above is a map of the United States showing the annual age-adjusted rates of acute lymphoblastic leukemia among persons aged <20 years, by state, based on data from the National Program of Cancer Registries and the Surveillance, Epidemiology, and End Results program, collected during 2001–2014.
FIGURE 2. Trends* in age-adjusted rates† of acute lymphoblastic leukemia in persons aged <20 years, by sex§ and race/ethnicity¶ — National Program of Cancer Registries, and Surveillance, Epidemiology, and End Results program, United States,** 2001–2014
* Trends were measured with annual percent change (APC) in rates, calculated using joinpoint regression, which allowed different slopes for as many as three different periods.
† Rates are per 1 million persons and age-adjusted to the 2000 U.S. standard population.
§ APC for acute lymphoblastic leukemia for both sexes and for males was significantly different from zero during 2001–2008.
¶ APC for acute lymphoblastic leukemia for Hispanics was significantly different from zero during 2001–2008.
** Incidence data are compiled from cancer registries that meet the data quality criteria for all years 2001–2014 (covering approximately 98% of the U.S. population). https://www.cdc.gov/cancer/npcr/uscs/data/00_data_quality.htm.
The figure above consists of two line graphs showing the trends in age-adjusted rates of acute lymphoblastic leukemia in U.S. persons aged <20 years, by sex and race/ethnicity, based on data from the National Program of Cancer Registries and the Surveillance, Epidemiology, and End Results program, collected during 2001–2014.
Suggested citation for this article: Siegel DA, Henley SJ, Li J, Pollack LA, Van Dyne EA, White A. Rates and Trends of Pediatric Acute Lymphoblastic Leukemia — United States, 2001–2014. MMWR Morb Mortal Wkly Rep 2017;66:950–954. DOI: http://dx.doi.org/10.15585/mmwr.mm6636a3External.
MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.
All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
Questions or messages regarding errors in formatting should be addressed to firstname.lastname@example.org.